Assembly Biosciences Inc（ASMB）股票分析ASMBAssembly Biosciences Inc

Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Assembly Biosciences Inc is currently not a good buy due to its low RSI of 29.414 indicating oversold conditions and a significant year-to-date change of -41.21%. While there is potential upside with analyst targets suggesting a price increase to $52-$53, the stock has shown a negative trend in recent performance and high volatility, making it risky at this time.